Insulin-Free Treatment For T2DM Patients
Dec 1, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Arjay Mendoza, PharmD Candidate, University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences
A new endoscopic duodenal mucosal resurfacing treatment could lead to T2D patients becoming insulin-free.
Endoscopic duodenal mucosal resurfacing (DMR), combined with glucagon-like peptide (GLP)-1 receptor agonist, has been shown to improve glycemic control in patients with T2DM, possibly enabling them to discontinue insulin therapy.
The scientific journal, gut, has published the one-year results of a small, international, open-label, prospective, multicenter clinical trial…
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.